Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00442832 · ClinicalTrials.gov registry record · Phase 2
TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
A Phase 2 study of Staphylococcal Skin Infection, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
- 1
- Study location
NCT00442832: Completed Phase 2 study of Staphylococcal Skin Infection, sponsored by Theravance Biopharma.
NCT00442832 is a Phase 2 study of Staphylococcal Skin Infection that has completed, run by Theravance Biopharma. The registered enrollment target is 203 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00442832, a Phase 2 study of Staphylococcal Skin Infection, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.
Conditions Studied
Interventions
- DRUG Vancomycin
- DRUG TD-1792
Study Locations (1)
California
- Allan Churukian - National City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
What the finished NCT00442832 record still lists
NCT00442832 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher).
The record links to 1 condition, with Staphylococcal Skin Infection appearing as the primary indexed condition, and to 2 interventions - of which Vancomycin is the first listed.
NCT00442832 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00442832 about?
NCT00442832 is a clinical study titled "TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection". The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.
What is the current status of trial NCT00442832?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2006-12. Estimated completion is 2007-05.
What conditions does trial NCT00442832 study?
This clinical trial studies the following conditions: Staphylococcal Skin Infection.
What interventions are being tested in trial NCT00442832?
The interventions under investigation include: Vancomycin (DRUG), TD-1792 (DRUG).
Who is sponsoring clinical trial NCT00442832?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00442832 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00442832's enrollment target sits among peer trials
203 301st of 2000 higher than 1,700 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia